{"id":1718,"date":"2025-05-23T12:00:43","date_gmt":"2025-05-23T04:00:43","guid":{"rendered":"https:\/\/www.hanchorbio.com\/?post_type=news&#038;p=1718"},"modified":"2025-11-10T17:22:24","modified_gmt":"2025-11-10T09:22:24","slug":"hanchorbio-to-present-interim-clinical-data-at-asco-2025-annual-meeting","status":"publish","type":"news","link":"https:\/\/www.hanchorbio.com\/en\/news\/hanchorbio-to-present-interim-clinical-data-at-asco-2025-annual-meeting\/","title":{"rendered":"HanchorBio to Present Interim Clinical Data at ASCO 2025 Annual Meeting"},"content":{"rendered":"<div>\u3010TAIPEI, SHANGHAI, and SAN FRANCISCO, May 23, 2025\u3011\u2013 HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announced that interim clinical data from its lead immunotherapy product, HCB101, has been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 \u2013 June 4 in Chicago, Illinois.<\/div>\n<div><\/div>\n<div>The accepted abstract (#2584: Phase 1 trial of HCB101, a novel Fc-based anti-SIRP\u03b1-CD47 fusion protein, in subjects with advanced cancers) highlights emerging data from the ongoing Phase 1 dose-escalation trial (NCT05892718) of HCB101, a differentiated SIRP\u03b1-Fc fusion protein rationally engineered to enhance phagocytosis and innate immune activation, without the hematologic toxicity that has hindered earlier CD47-targeting therapies. HCB101 is being evaluated as monotherapy in patients with advanced solid tumors or relapsed\/refractory (R\/R) non-Hodgkin lymphomas (NHLs). The poster presentation is scheduled for June 2, 2025, during the ASCO Immunotherapy session.<\/div>\n<div><\/div>\n<div>\u201cHCB101 was designed to unlock the full potential of macrophage checkpoint inhibition by overcoming key limitations of legacy CD47 programs,\u201d said Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio. \u201cThe ASCO presentation represents an important step in our strategy to build durable, best-in-class immunotherapies driven by innate immunity. We look forward to engaging with the oncology community, including scientific leaders, collaborators, and potential partners, as we advance HCB101 into the next phase of clinical development.\u201d<\/div>\n<div><\/div>\n<div>HCB101 was developed using HanchorBio\u2019s proprietary FBDB\u2122 platform, which combines Fc engineering and SIRP\u03b1 optimization to achieve high-affinity binding and immune effector activation. Preclinical studies demonstrated robust anti-tumor activity and favorable tolerability, supporting its clinical advancement.<\/div>\n<div><\/div>\n<div>HanchorBio is actively exploring strategic collaborations to accelerate global development and unlock the full potential across oncology and autoimmune indications.<\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announced that interim clinical data from its lead immunotherapy product, HCB101, has been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 \u2013 June 4 in Chicago, Illinois. The accepted abstract (#2584: Phase 1 trial of HCB101, a novel Fc-based anti-SIRP\u03b1-CD47 fusion protein, in subjects with advanced cancers) highlights emerging data from the ongoing Phase 1 dose-escalation trial (NCT05892718) of HCB101, a differentiated SIRP\u03b1-Fc fusion protein rationally engineered to enhance phagocytosis and innate immune activation, without the hematologic toxicity that has hindered earlier CD47-targeting therapies. HCB101 is being evaluated as monotherapy in patients with advanced solid tumors or relapsed\/refractory (R\/R) non-Hodgkin lymphomas (NHLs). The poster presentation is scheduled for June 2, 2025, during the ASCO Immunotherapy session.<\/p>\n","protected":false},"featured_media":0,"template":"","news-category":[],"class_list":["post-1718","news","type-news","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news\/1718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:attachment":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media?parent=1718"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news-category?post=1718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}